Mutational dynamics of SARS-CoV-2 in Austria
Andreas Bergthaler | Center for Molecular Medicine (CeMM)
(in collaboration with: Medical University of Vienna; Austian Agency for Health and Food Safety Ltd. (AGES) and other Austrian universities)
If you have any questions about the Call and the WWTF, please contact Michael Stampfer.
(in collaboration with: Medical University of Vienna; Austian Agency for Health and Food Safety Ltd. (AGES) and other Austrian universities)
(in collaboration with: Oliver H. Robak, Medical Univeristy of Vienna; Christoph Steininger,Medical Univeristy of Vienna; Christof Jungbauer, Austrian Red Cross; Volker Witt, St. Anna Children's Hospital; Hedda Wardemann, German Cancer Research Center (DKFZ); Florian Halbritter, Children's Cancer Research Insitute (CCRI); Matthias Farlik-Födinger, Medical Univeristy of Vienna)
(In collaboration with: Josef Penninger, University of British Columbia, IMBA & Apeiron; Johannes Stadlmann, IMBA & University of Natural Resources and Life Sciences)
The initial interaction of SARS-CoV-2 with human cells results from a protein-protein interaction between the SARS-CoV-2 Spike protein and the human Ace2 receptor. Promising novel pharmaceutics are based on solubilized versions of the Ace2 receptor, potentially blocking the virus proteins and hindering an interaction with human Ace2 present on the cells. We have created a complete model of the Spike-Ace2 interaction, with full glycosylation. The model confirms that the glycans can play a significant role in the interaction. In particular, there is evidence that removal of the N90 glycan strengthens the interaction. This offers possibilities to engineer the therapeutic proteins to show stronger interactions with Spike and therefore be more effective.
We will create computer models of Spike – Ace2 interactions with different variants of Ace2. This includes species-specific variations (mouse Ace2 seems not to interact with Spike), naturally occurring genetic modifications, and alternative therapeutic formats.
Funding: € 24,547
Duration: 1 April 2020 - 30 September 2020
Contact and project details: https://boku.ac.at/map/mms/forschung/sars-cov-2-related-research
(in collaboration with: Ali Mirazimi, Karolinska Institutet; Nuria Montserrat, Institute for Bioengineering of Catalonia (IBEC), Apeiron Biologics)
(in Kooperation mit Miriam Klausberger, University of Natural Resources and Life Sciences; Reingard Grabherr, University of Natural Resources and Life Sciences; Florian Grebien, Vetmeduni Vienna; Heinz Burgmann, Medical University of Vienna)
(in collaboration with: Max Perutz Labs, a Joint Venture of the Univeristy of Vienna and the Medical University of Vienna; University of Vienna; IMP; IMBA; GMI and other institutions in Vienna)
(in collaboration with: Julius Brennecke, IMBA; Andrea Pauli, IMP; Ulrich Elling, IMBA; Stefan Ameres, IMBA; Alwin Köhler, University of Vienna/VCDI; Manuela Födinger (KFJ/KAV))
(in collaboration with: Wiener Krankenanstaltenverbund, Sigmund Freud Universität)
(in collaboration with: Complexity Science Hub; dwh GmbH; SpotOn Statistics GmbH, Statistik Austria)
(in collaboration with: Richard Crevenna, Medical University of Vienna; Maren Jeleff, Medical University of Vienna; Elena Jirovsky, Medical University of Vienna)
(in collaboration with: Medical University of Vienna)
(in collaboration with: David Garcia, Complexity Science Hub (CSH) and Medical University of Vienna)
(in collaboration with: Erika Mosor, Valentin Ritschl, Maisa Omara, Martin Posch, Franz König, Matthias Wielscher and Michael Hiesmayr, Medical University of Vienna; Susanne Perkhofer, FHG Innsbruck; Michael Schirmer, Medical University of Innsbruck; Angelika Rzepka, Bernhard Pfeifer, Peter Kastner and Anton Dunzendorfer, Austrian Institute of Technology; Florian Stigler and Martin Sprenger, Medical University of Graz; Siegfried Walch and Nils Mevenkamp, Management Center Innsbruck)
(in collaboration with: Sylvia Kritzinger, University of Vienna; Hajo Boomgaarden, University of Vienna; Barbara Prainsack, University of Vienna)
(in collaboration with: Institut for Socialanthropolog Austrian Academy of Sciences)
(in collaboration with: Arbeiterkammer Wien; Frauenabteilung)
(in collaboration with: Marko Lüftenegger, University of Vienna; Christiane Spiel, University of Vienna)
(in collaboration with Fraunhofer Austria; Bundesministerium für Digitalisierung und Wirtschaftsstandort; Bundeministerium für Landwirtschaft, Regionen und Tourismus; Universität Salzburg; Universität Klagenfurt)
(in collaboration with: Thomas Lindner, Jakob Müllner, Michael Wolfesberger (WU Vienna); Andreas König, Universität Passau; Oesterreichische Nationalbank (OeNB); Wirtschaftskammer Österreich (WKO))
(in cooperation with: Manfred Gronalt, Medical University of Vienna; Beate Pinior, University of Natural Resources and Life Sciences; Vetmeduni Vienna)